Overview

* WELL Health ( WHTCF ) Q3 revenue grows 56% yr/yr but misses analyst expectations

* Adjusted EBITDA for Q3 rises 296% to C$59.9 mln

* Company reaffirms annual revenue and adjusted EBITDA guidance

Outlook

* WELL reaffirms 2025 revenue guidance of C$1.40 bln to C$1.45 bln

* Company expects 2025 Adjusted EBITDA in upper half of C$190 mln to C$210 mln

* WELL's guidance sensitive to M&A and divestitures timing

Result Drivers

* CANADIAN PERFORMANCE - Strong performance in core Canadian businesses drove record revenue and adjusted EBITDA

* TECHNOLOGY INTEGRATION - AI-enabled technology improved operational efficiency and patient visit metrics

* WELLSTAR GROWTH - WELLSTAR subsidiary's growth supported by recent financing and strategic initiatives

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss C$364.60 C$374.50

Revenue mln mln (14

Analysts

)

Q3 C$0.16

Adjusted

EPS

Q3 C$41 mln

Adjusted

Net

Income

Q3 Net -C$2.65

Income mln

Q3 C$59.92

Adjusted mln

EBITDA

Q3 45.50%

Adjusted

Gross

Margin

Q3 C$165.77

Adjusted mln

Gross

Profit

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", 1 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the healthcare facilities & services peer group is "buy"

* Wall Street's median 12-month price target for WELL Health Technologies Corp ( WHTCF ) is C$7.80, about 37.2% above its November 5 closing price of C$4.90

* The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 28 three months ago

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)